Trial Profile
A Phase 1/2, Open-label, Multi-center Study to Assess the Safety and Tolerability of Durvalumab (Anti-PDL1 Antibody) as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocitic Leukemia
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 20 Nov 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Bendamustine; Ibrutinib; Lenalidomide; Rituximab
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Lymphoma; Mantle-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms FUSION NHL 001
- Sponsors Celgene Corporation
- 16 Dec 2022 Status changed from active, no longer recruiting to completed.
- 18 Sep 2022 This trial has been completed in Netherlands, according to European Clinical Trials Database record (21 Aug 2022).
- 25 Jan 2022 Planned End Date changed from 8 Jul 2022 to 21 Aug 2022.